Qrons (QRON) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 13, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Qrons Inc.
Entity Central Index Key	0001689084
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Interactive Data Current	Yes
Entity File Number	000-55800
Entity Shell Company	false
Entity Incorporation State Country Code	WY
Entity Common Stock, Shares Outstanding		13,079,809

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 47,496	$ 143,862
Prepaid expenses	32,716	51,985
Total current assets	80,212	195,847
TOTAL ASSETS	80,212	195,847
Current liabilities
Accounts payable and accrued liabilities	83,580	23,324
Accounts payable and accrued liabilities - related party	56,735	3,421
Demand loans, related party	50,000
Advances from related party	100,000
Unsecured short-term advances	100,000
Convertible note - related party, net of debt discount	25,000	25,000
Derivative liabilities	44,456	36,827
Total current liabilities	459,771	88,572
Total liabilities	459,771	88,572
Stockholders' equity (deficit)
Series A Preferred Shares: $0.001 par value, authorized 10,000; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: shares authorized 100,000,000; 13,079,809 and 12,872,309 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	1,308	1,287
Additional Paid-in Capital	6,076,041	5,629,694
Accumulated deficit	(6,456,910)	(5,523,708)
Total stockholder's equity (deficit)	(379,559)	107,275
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 80,212	$ 195,847

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,079,809	12,872,309
Common stock, shares outstanding	13,079,809	12,872,309

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net sales
Operating expenses:
Research and development expenses	136,080	150,469	439,608	360,586
Professional fees	14,928	6,300	58,154	35,449
General and administrative expenses	308,735	377,545	424,652	1,310,164
Total operating expenses	459,743	534,314	922,414	1,706,199
Net (loss) from operations	(459,743)	(534,314)	(922,414)	(1,706,199)
Other income (expense)
Interest expense	(1,243)	(6,048)	(3,159)	(19,839)
Change in derivative liabilities	6,828	(2,979)	(7,629)	584
Total other (expense)	5,585	(9,027)	(10,788)	(19,255)
Net (loss)	$ (454,158)	$ (543,341)	$ (933,202)	$ (1,725,454)
Net (loss) per common shares (basic and diluted)	$ (0.04)	$ (0.04)	$ (0.07)	$ (0.14)
Weighted average shares outstanding (basic and diluted)	12,966,485	12,807,584	12,938,828	12,744,561

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Shares	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 2	$ 1,240	$ 1,611,711	$ (1,592,680)	$ 20,273
Balance, shares at Dec. 31, 2017	2,000	12,404,910
Issuance of common stock for private placement		$ 32	499,968		500,000
Issuance of common stock for private placement, shares		312,500
Warrants exercised associated with private placement
Warrants exercised associated with private placement, shares		1,715
Shares issued for stock awards for business advisory services		$ 1	27,999		28,000
Shares issued for stock awards for business advisory services, shares		10,000
Stock option granted to officers			353,430		353,430
Stock option granted to non-employees as research and development costs			27,975		27,975
Net loss for the year				(493,470)	(493,470)
Balance at Mar. 31, 2018	$ 2	$ 1,273	2,521,083	(2,086,150)	436,208
Balance, shares at Mar. 31, 2018	2,000	12,729,125
Balance at Dec. 31, 2017	$ 2	$ 1,240	1,611,711	(1,592,680)	20,273
Balance, shares at Dec. 31, 2017	2,000	12,404,910
Net loss for the year					(1,725,454)
Balance at Sep. 30, 2018	$ 2	$ 1,283	3,497,774	(3,318,134)	180,925
Balance, shares at Sep. 30, 2018	2,000	12,826,853
Balance at Dec. 31, 2017	$ 2	$ 1,240	1,611,711	(1,592,680)	$ 20,273
Balance, shares at Dec. 31, 2017	2,000	12,404,910
Warrants exercised associated with private placement, shares					1,715
Balance at Dec. 31, 2018	$ 2	$ 1,287	5,629,694	(5,523,708)	$ 107,275
Balance, shares at Dec. 31, 2018	2,000	12,872,309
Balance at Mar. 31, 2018	$ 2	$ 1,273	2,521,083	(2,086,150)	436,208
Balance, shares at Mar. 31, 2018	2,000	12,729,125
Shares issued for services provided		$ 7	149,993		150,000
Shares issued for services provided, shares		75,000
Shares issued for stock awards to officers			353,430		353,430
Stock option granted to non-employees as research and development costs			46,763		46,763
Net loss for the year				(688,643)	(688,643)
Balance at Jun. 30, 2018	$ 2	$ 1,280	3,071,269	(2,774,793)	297,758
Balance, shares at Jun. 30, 2018	2,000	12,804,125
Issuance of common stock for private placement		$ 3	24,997		25,000
Issuance of common stock for private placement, shares		22,728
Stock option granted to officers			353,430		353,430
Stock option granted to non-employees as research and development costs			48,078		48,078
Net loss for the year				(543,341)	(543,341)
Balance at Sep. 30, 2018	$ 2	$ 1,283	3,497,774	(3,318,134)	180,925
Balance, shares at Sep. 30, 2018	2,000	12,826,853
Balance at Dec. 31, 2018	$ 2	$ 1,287	5,629,694	(5,523,708)	107,275
Balance, shares at Dec. 31, 2018	2,000	12,872,309
Issuance of common stock for private placement		$ 4	39,996		40,000
Issuance of common stock for private placement, shares		40,000
Shares issued for stock awards for business advisory services		$ 3	37,497		37,500
Shares issued for stock awards for business advisory services, shares		30,000
Stock option granted to non-employees as research and development costs			45,442		45,442
Net loss for the year				(261,461)	(261,461)
Balance at Mar. 31, 2019	$ 2	$ 1,294	5,752,629	(5,785,169)	(31,244)
Balance, shares at Mar. 31, 2019	2,000	12,942,309
Balance at Dec. 31, 2018	$ 2	$ 1,287	5,629,694	(5,523,708)	107,275
Balance, shares at Dec. 31, 2018	2,000	12,872,309
Net loss for the year					(933,202)
Balance at Sep. 30, 2019	$ 2	$ 1,308	6,076,041	(6,456,910)	(379,559)
Balance, shares at Sep. 30, 2019	2,000	13,079,809
Balance at Mar. 31, 2019	$ 2	$ 1,294	5,752,629	(5,785,169)	(31,244)
Balance, shares at Mar. 31, 2019	2,000	12,942,309
Issuance of common stock for private placement		$ 3	24,997		25,000
Issuance of common stock for private placement, shares		25,000
Stock option granted to non-employees as research and development costs			42,491		42,491
Net loss for the year				(217,583)	(217,583)
Balance at Jun. 30, 2019	$ 2	$ 1,297	5,820,117	(6,002,752)	(181,336)
Balance, shares at Jun. 30, 2019	2,000	12,967,309
Shares issued for services provided		$ 5	74,495		74,500
Shares issued for services provided, shares		50,000
Shares issued for stock awards for business advisory services		$ 2	40,248		40,250
Shares issued for stock awards for business advisory services, shares		25,000
Shares issued for stock awards to officers		$ 4	49,121		49,125
Shares issued for stock awards to officers, shares		37,500
Stock option granted to officers			53,307		53,307
Stock option granted to non-employees as research and development costs			38,753		38,753
Net loss for the year				(454,158)	(454,158)
Balance at Sep. 30, 2019	$ 2	$ 1,308	$ 6,076,041	$ (6,456,910)	$ (379,559)
Balance, shares at Sep. 30, 2019	2,000	13,079,809

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows From Operating Activities
Net loss	$ (933,202)	$ (1,725,454)
Adjustments to reconcile net loss to net cash (used by) operating activities:
Stock issued for advisory and consulting services	201,375	178,000
Stock options granted for research and development expense	126,686	122,816
Stock options granted for administrative expenses and advisory services	53,307	1,060,290
Accretion of debt discount		18,335
Change in derivative liabilities	7,629	(584)
Changes in operating assets and liabilities:
Prepaid expenses	19,269	(39,179)
Accounts payable and accrued liabilities	60,256	126
Accounts payable and accrued liabilities, related party	53,314	1,505
Net cash (used by) operating activities	(411,366)	(384,145)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities
Cash Flows From Financing Activities
Proceeds from private placements	65,000	525,000
Proceeds from short term advance, third party	100,000
Proceeds from demand loan, related party	50,000
Proceeds from related party advances	100,000
Net cash provided from financing activities	315,000	525,000
Increase (decrease) in cash and cash equivalents	(96,366)	140,855
Cash at beginning of period	143,862	57,767
Cash at end of period	47,496	198,622
SUPPLEMENTAL DISCLOSURES
Interest paid
Income taxes paid

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and nature of business: Qrons Inc. ("Qrons" or the "Company") was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. On July 6, 2017, the board of directors and a majority of the Company's shareholders approved an amendment to the Company's Articles of Incorporation to change the name of the Company from "BioLabMart Inc." to "Qrons Inc.". On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. The Company's common stock was approved by the Financial Industry Regulatory Authority ("FINRA") for quotation on the OTC pink sheets under the symbol "BLMB" as of July 3, 2017. FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol change to "QRON" for the OTC Market was effective August 10, 2017. The Company's common stock was upgraded from the Pink Market and commenced trading on the OTCQB Venture Market on August 12, 2019. The common stock will continue to be traded under the symbol "QRON". The Company is an emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries ("TBIs") and concussions. To date, the Company has two product candidates for treating penetrating and non-penetrating (concussion-like) TBIs, both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified mesenchymal stem cells ("MSCs"). QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company collaborates treatment that integrates proprietary, engineered MSCs, synthetic hydrogels, 3D printable implant and a novel delivery system. On March 15, 2019, the Company relocated its principal executive office from Miami, Florida to 50 Battery Place, #7T, New York, New York 10280.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statement Presentation: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Reclassification: Fiscal year end: Use of Estimates: Cash Equivalents: Research and Development Costs: esearch and development costs were $150,569 and $360,586 for . Advertising and Marketing Costs: The Company incurred $190,362 and $7,907 in advertising and marketing costs during the three months ended September 30, 2019 and 2018, respectively. The Company incurred $280,952 and $48,832 in advertising and marketing costs during the nine months ended September 30, 2019 and 2018, respectively. Related parties: Stock-Based Compensation and Other Share-Based Payments: The Company accounts for stock compensation arrangements with non-employees in accordance with ASU 2018-07 which requires that such equity instruments are recorded at the value on the grant date. For stock options granted to employees, directors, and non-employees, the fair value of the stock options is estimated using a Black-Scholes valuation model. Fair Value of Financial Instruments FASB ASC 820, "Fair Value Measurements and Disclosures", defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company's derivative liabilities as of September 30, 2019 and December 31, 2018: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2019: Liabilities Derivative liabilities $ - $ - $ 44,456 As of December 31, 2018: Liabilities Derivative liabilities $ - $ - $ 36,827 Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity" Income taxes: Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the periods ended September 30, 2019 and December 31, 2018 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: September 30, 2019 December 31, 2018 Stock purchase warrants 52,000 52,000 Research Warrants at 3% of issued and outstanding shares 392,394 386,170 Convertible Notes 37,690 27,864 Series A Preferred shares 700 700 Stock options vested 1,553,336 1,486,670 Stock options not yet vested 161,664 128,330 Total 2,197,784 2,081,734 New Accounting Pronouncements: In June 2018, an accounting update was issued by FASB to simplify the accounting for nonemployee share-based payment transactions resulting from expanding the scope of ASC Topic 718, "Compensation-Stock Compensation ASC Topic 718 ASC Topic 718 ASC Topic 718 ASC Topic 606, Revenue from Contracts with Customers

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date, and it has not generated revenue from operations. While the Company raised proceeds during fiscal 2018 and during the nine months of 2019, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the fourth quarter of fiscal 2019. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Convertible Note - Related Part

Convertible Note - Related Party and Derivative Liabilities	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Convertible Note - Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with CubeSquare, LLC ("CubeSquare"). The Company's Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 ("Note 1"). The note bears interest at 8% per annum and was due on September 1, 2017. Any portion of the loan and unpaid interest is payable in cash or convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to (i) the greater of a discountof 75% to $0.25 per share or $0.0625 per share if the Company's shares are not trading on a public market; and (ii) if the shares are listed for trading on a public market a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion. On September 28, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; and on September 1, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020, under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and is due on September 27, 2018. Interest shall accrue from September 27, 2017 and shall be payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion. On September 9, 2018, Note 2 was amended to extend the maturity date until September 27, 2019. On September 27, 2019, Note 2 was amended to extend the maturity date until September 27, 2020. The Company analyzed the amendment to Note 1 and Note 2 under and concluded that these two convertible debentures We estimated the fair value of the derivative on the inception dates, and subsequently, using the Black-Scholes valuation technique, adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms, and risk-free rates) that are necessary to fair value complex derivate instruments. The carrying value of these convertible notes is as follows: September 30, 2019 December 31, 2018 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - - Carrying value $ 25,000 $ 25,000 As a result of the application of ASC No. 815 in the periods ended September 30, 2019 and December 31, 2018 the fair value of the conversion feature is summarized as follows: Balance at December 31, 2017 $ 31,090 Derivative addition associated with convertible notes - Change in fair value 5,737 Balance at December 31, 2018 36,827 Change in fair value 7,629 Balance at September 30, 2019 $ 44,456 The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of September 30, 2019 and commitment date: Commitment Date September 30, 2019 December 31, 2018 Expected dividends 0 0 0 Expected volatility 101% ~103% 206.53% ~ 214.23% 64% ~ 65% Expected term 0.92 ~ 1 year 0.92 ~ 0.99 year 0.67 ~ 0.74 year Risk free interest rate 1.33% 1.75% 2.60%

Unsecured Short-Term Advance fr

Unsecured Short-Term Advance from Third Party	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Unsecured Short-Term Advance from Third Party	Note 5 – Unsecured Short-Term Advance from Third Party On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest bearing, short term advance to meet its operating needs. The advance remains outstanding at September 30, 2019.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Demand Loan from Related Party On May 1, 2019, the Company issued a promissory note (the "Note") to CubeSquare in the principal amount of $50,000. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare.

License and Research Funding Ag

License and Research Funding Agreements	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
License and Research Funding Agreements	Note 7 – License and Research Funding Agreements On December 14, 2016, the Company entered into a license agreement with Ariel (the "License Agreement") under which the Company paid Ariel $100,000 to fund research for 12 months (with an option to extend such research financing and research period). In consideration therefore, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating coral-based conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding in accordance with milestones set forth in the Agreement. In addition, upon the occurrence of an Exit Event (as defined in the License Agreement) of the Company or of any affiliate commercializing the products, the Company is obligated to issue to Ariel an immediately exercisable warrant for that number of shares equal to 4% of the issued and outstanding shares of the Company at the time of issuance. The Company and Ariel entered into Addendum #1 to the License Agreement, effective December 13, 2017 (the "Addendum") pursuant to which Ariel was permitted to exercise a portion of the warrant granted pursuant to the License Agreement. On December 13, 2017, the Company issued 119,950 shares of common stock to Ariel, representing 1% of the issued and outstanding shares of the Company on such date, and valued at $335,860. The right to the balance of the shares subject to the warrant remains subject to the terms of the License Agreement and the occurrence of an Exit Event (as described in the License Agreement). In addition, the Addendum provides that Ariel may not request a demand registration until the balance of the shares subject to the warrant is exercised. In addition to the other payments, the Company will pay Ariel upon the occurrence of the following milestone events, additional payments which shall be due within 6 months of completion of the milestone: - Upon successful clinical FDA Phase II completion - $130,000; and - Upon successful clinical FDA Phase III completion - $390,000 Upon successful development and commercialization and in recognition of the rights and licenses granted to the Company pursuant to the License Agreement, the Company will be subject to certain royalty payments as specified in the License Agreement. In lieu of extending the research financing and research period under the License Agreement with Ariel beyond the initial 12 months, on December 14, 2017, the Company entered into the Services Agreement pursuant to which a team at Ariel University under the direction of Professor Danny Baranes will conduct molecular biology research activities involving the testing of scaffold materials for the Company. As compensation for such services, the Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. On March 6, 2018, the Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. On December 12, 2018, the Company further amended the Services Agreement (the "Second Amendment") with Ariel to extend the term thereof for an additional twelve-month period until December 14, 2019. The Second Amendment also provides that the Company pay Ariel $17,250 within 30 days of the date of the Amendment and an additional $17,250 on or before May 1, 2019. All other terms and conditions of the Services Agreement not amended remain in effect. On July 12, 2018, the Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement") with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement. On November 4, 2019, the parties entered into an amendment to the Sponsored Research Agreement to extend the term of the Agreement through July 14, 2020.

Intellectual Property License A

Intellectual Property License Agreement	9 Months Ended
	Sep. 30, 2019
Intellectual Property License Agreement [Abstract]
Intellectual Property License Agreement	Note 8 – Intellectual Property License Agreement On October 2, 2019, the Company entered into an Intellectual Property License Agreement (the "Agreement") with the Trustees of Dartmouth College ("Dartmouth") pursuant to which, effective September 3, 2019 (the Effective Date"), Dartmouth granted the Company an exclusive world-wide license under the patent application entitled "Mechanically Interlocked Molecules-based Materials for 3D Printing" in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement. Dartmouth has reserved certain rights in its intellectual property for educational and research purposes. As consideration for the license grant, the Company will pay Dartmouth: (i) a license issue fee of $25,000; (ii) an annual license maintenance fee of $25,000, commencing on the first anniversary of the Effective Date until the date of the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales (as defined in the Agreement) of licensed products and services by the Company or a sublicensee; (v)15% of all consideration received by the Company under a sublicense; and (vi) beginning as of the date of the first commercial sale, an annual minimum royalty payment of $500,000 in the first calendar year after the first commercial sale, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs. Under the Agreement, the Company must diligently proceed with the development, manufacture and sale of licensed products and licensed services, including funding at least $1,000,000 of research in each calendar year beginning in 2019 and ending with the first commercial sale of a licensed product; filing an IND/BLA (or equivalent) with the FDA or a comparable European regulatory agency before the four-year anniversary of the Effective Date, make the first commercial sale of a licensed product before the twelve-year anniversary of the Effective Date and achieve annual net sales of at least $50,000,000 by 2033. If the Company fails to perform any of these obligations, Dartmouth has the option to terminate the Agreement or change the exclusive license to a nonexclusive license. Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law. The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth. If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate. The Agreement also includes indemnification and insurance requirements by the Company and customary confidentiality provisions. The Company recorded the $25,000 license fee under prepaid expenses, which amount shall be expensed ratably over the initial one-year term of the Agreement.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 9 – Commitments (1) Service Agreement with Ariel Scientific Innovations Ltd. On December 14, 2017, the Company entered into the Services Agreement pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. As compensation for the services provided, the Company will pay Ariel (i) $17,250 within five business days of the execution of the Services Agreement, and (ii) $17,250 by May 1, 2018. The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for five years after the term of the Services Agreement. During the year ended December 31, 2017, $17,250 was paid and on April 26, 2018, the remaining installment of $17,250 was paid. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to $2,200 (8,000 Israeli shekels) as compensation for additional costs which the Company may request. During the year ended December 31, 2018, the Company paid $16,935 for these additional costs. On December 12, 2018, the Company further amended the Services Agreement with Ariel (the "Second Amendment") to extend the term thereof for an additional twelve-month period until December 14, 2019. The Second Amendment also provides that the Company pay Ariel $17,250 within 30 days of the date of the Amendment and an additional $17,250 on or before May 1, 2019. All other terms and conditions of the Services Agreement not amended remain in effect. During the nine months ended September 30, 2019 and 2018, $26,594 and $49,885 were expensed, respectively, and the remaining $7,187 (December 31, 2018 - $16,531), which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in a subsequent period. (2) Service Agreement with Ariel - Dr. Gadi Turgeman On March 6, 2018, the Company entered into a service agreement for the services of Professor Gadi Turgeman and his neurobiology research team in their lab. As compensation for the services provided, the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement. On April 11, 2019, the Company amended its services agreement (the "First Amendment") with Ariel which it entered into on March 6, 2018, to extend the term thereof for an additional twelve months until March 6, 2020. Pursuant to the First Amendment, the Company will pay Ariel an aggregate of $41,160 in quarterly payments of $10,290 on each of April 11, 2019, June 1, 2019, September 1, 2019 and December 1, 2019 for the services of Professor Gadi Turgeman and his neurobiology research team and the use of his lab. During the nine months ended September 30, 2019 and 2018, $27,440 and $24,010 were expensed, respectively, and the remaining $0 (December 31, 2018 - $6,860), which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in a subsequent period. (3) Science Advisory Board Member Consulting Agreements (the " Consulting Agreements") As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company's technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board and Business Advisory Board as described below, and the Company and Advisors have entered into Consulting Agreements with the following terms and conditions: - Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the "Services") as a member of its Scientific Advisory Board ("SAB"). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company's SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company's scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor's consultation with Company will involve services as scientific, technical and business advisor to the Company and its management with respect to neuronal injuries and neuro degenerative diseases. - SAB Consulting Compensation - the Company shall grant to Advisor the option to purchase certain number of shares of the common stock of the Company as per the stock option award grant. The options are subject to terms and provisions of the Company's 2016 Stock Option and Stock Award Plan. On November 15, 2017, the Company entered into Consulting Agreements with three Advisors under the terms of which two Advisors are granted an option to purchase 20,000 shares of common stock and one Advisor was granted an option to purchase 30,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms. On April 16, 2018, the Company entered into a Consulting Agreement with an Advisor to serve on the Company's Scientific Advisory Board under the terms of which the Advisor was granted an option to purchase 30,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms. On August 15, 2018, the Company entered into a Consulting Agreement with an Advisor under the terms of which the Company granted an option to purchase 20,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms. (4) Business Advisory Board Agreement On January 23, 2018, the Company entered into a one-year advisory board member consulting agreement with Pavel Hilman, the controlling shareholder of Conventus Holdings SA, a BVI corporation ("Conventus"), under which Mr. Hilman will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan. On January 28, 2019, the Company issued 30,000 shares of common stock to Pavel Hilman for his continuing service on the Company's Advisory Board. On September 18, 2019, the Company entered into a one-year advisory board member consulting agreement with Derrick Chambers under which Mr. Chambers will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 25,000 shares of its common stock to Mr. Chambers under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance. (5) Investor Relations Agreement On April 23, 2018, the Company entered into a six-month investor relations agreement with an investor relations firm for a monthly consulting fee of $5,000 and the issuance of 75,000 shares of common stock payable on signing the agreement. On June 23, 2018, the Company gave notice of rescission of the agreement to such firm. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue. (6) Sponsored Research Agreement On July 12, 2018, the Company entered into a one-year Sponsored Research Agreement with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and funded an additional $18,147 on December 17, 2018 and funded an additional $18,146 on June 20, 2019. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement. On November 4, 2019, the parties entered into an amendment to the Sponsored Research Agreement to extend the term of the Agreement through July 14, 2020. During the nine months ended September 30, 2019 and 2018, $45,366 and $9,073 were expensed, respectively, and the remaining $0 (December 31, 2018 - $27,220), which amount is reflected on the Company's balance sheets as prepaid expenses, was expensed in the applicable period. (7) Investor Relations Agreement On August 8, 2019, the Company entered into a six-month services agreement with PCG Advisory, Inc. ("PCG") under which agreement PCG will provide investor relations and capital market advisory services to the Company. In consideration therefor, the Company will pay PCG a monthly cash fee of $5,000 ($2,500 of which will be deferred until the Company raises at least $300,000 in a financing) and issued 50,000 shares of its common stock on August 8, 2019.After the initial six-month term, the agreement will automatically renew on a month-to-month basis unless either party notifies the other of its desire to terminate the agreement or by the Company if PCG fails to comply with securities laws, makes an untrue statement of material facts or omits to state any material fact in connection with an investment in the Company or breaches a representation, warranty or covenant in the agreement.

Stock Plan

Stock Plan	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock Plan	Note 10 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company's 2016 Stock Option and Stock Award Plan (the "Plan"). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Administrator of the Plan appointed by the Company's Board of Directors (the "Board"), or in the absence of an Administrator, by the Board. The Company has reserved 10 million shares for issuance under the Plan. Stock Awards: On December 14, 2016, the Board awarded to each of Prof. Danny Baranes, a Science Advisor, and Dr. Liat Hammer, a former Science Advisor, a total of 440,000 shares of common stock of which 150,000 shares vested on December 14, 2016 and 145,000 shares vested on December 14, 2017. The balance of 145,000 shares did not vest as the nature of such services in such capacities were no longer provided to the Company. The value of the vested awards had been recorded as research and development expenses in the respective periods. A total of 290,000 stock awards did not vest during the fourth quarter of fiscal 2018. On January 23, 2018, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance. On January 28, 2019, the Company issued 30,000 shares of common stock to Pavel Hilman for his continuing service on the Company's Board of Advisors. In connection with the Term Sheet, on July 1, 2019, Dr. Bonfiglio was granted (i) 50,000 shares of common stock of the Company, 37,500 of which shares vested upon issuance on July 1, 2019 and 12,500 of which shares will vest on the earlier of (i) January 1, 2020 and (ii) the date the Company raises equity capital of $500,000, provided Dr. Bonfiglio is in the employ of the Company on such date. On September 18, 2019, the Company awarded 25,000 shares of common stock to Derrick Chambers, a member of its advisory board, under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance. September 30, September 30, 2019 2018 Number of shares vested in period 92,500 10,000 Weighted average fair market value per share $ 1.37 $ 2.8 Stock based compensation recognized $ 126,875 $ 28,000 Stock Options: (a) Stock Options granted to Science Advisors: On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company. On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company. On April 16, 2018, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. On August 15, 2018, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 6,667 shares of common stock, exercisable on August 15, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 6,667 shares of common stock exercisable on August 15, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 6,666 shares of common stock exercisable on August 15, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. (b) Stock Options granted to Employees: On December 10, 2018, under the 2016 Stock Option and Award Plan, the Board granted an immediately exercisable five-year option purchase an aggregate of 145,000 shares of common stock at an exercise price of $2.00 per share to as a "replacement award" for the same number of shares which did not vest as described in Note 7-Stock Awards. Applying the On December 10, 2018, under the 2016 Stock Option and Award Plan, the Board awarded an employee the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. The following table is the recognized compensation in respect of the above stock option compensation ((a) and (b)) which amount has been allocated as below: Three Months ended Nine Months ended September 30, September 30, 2019 2018 2019 2018 Research and development expenses $ 38,753 $ 48,078 $ 126,686 $ 122,816 A s of September 30, 2019, total unrecognized compensation remaining to be recognized in future periods totaled $71,402. (c) Stock Options granted to Officers: On December 4, 2017, the Board granted five-year options to each of its two officers for the purchase of 300,000 shares of the common stock of the Company . The options have an exercise price of $2.00 and vest and become exercisable on December 4, 2018. On December 10, 2018, the Board granted five-year options to each of its two officers . The options have an exercise price of $2.00 and are immediately exercisable. On June 25, 2019, the Company entered appointed John N. Bonfiglio, PhD as its chief operating officer, effective July 1, 2019. As compensation Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares will vest upon grant and 25,000 shares will vest on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio is in the employ of the Company on such dates and further provided that if the Company raises equity capital of $1.5 million before December 31, 2019, unvested shares subject to the option will immediately vest and become exercisable, so long as Dr. Bonfiglio is in the Company's employ on such date. The following table is the recognized compensation in respect of the above stock option compensation, which amounts have been allocated as general and administrative expenses Three Months ended Nine Months ended September 30, September 30, 2019 2018 2019 2018 General and administrative expenses $ 53,307 $ 353,430 $ 53,307 $ 1,060,290 As of September 30, 2019, total unrecognized compensation remaining to be recognized in future periods totaled $36,473. The fair value of each option award referenced above is estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 114.69 ~ 129.08% Risk-free interest rate 1.79% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 1.31 ~ 2.80 Exercise Price $ 0.40 ~ 2.00 A summary of the activity for the Company's stock options at September 30, 2019 and December 31, 2018, is as follows: September 30, 2019 December 31, 2018 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 1,615,000 $ 1.97 670,000 $ 1.93 Granted 100,000 $ 2 945,000 $ 2.00 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 1,715,000 $ 1.97 1,615,000 $ 1.97 Options exercisable, end of period 1,553,336 $ 1.98 1,486,670 $ 1.98 Options expected to vest, end of period 161,664 $ 1.85 128,330 $ 1.81 Weighted average fair value of options granted $ 2.12 $ 2.19

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Capital Stock	Note 11 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001 and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on There was a total of 2,000 shares of Series A Preferred Stock issued and outstanding as of September 30, 2019 and December 31, 2018. Common Stock Common Stock issuances during the nine months ended September 30, 2019 During the nine months ended September 30, 2019, the Company sold an aggregate of 65,000 shares of its common stock to investors and received aggregate proceeds of $65,000 pursuant to subscription agreements in private offerings. The proceeds will be used for research and general corporate purposes. On January 28, 2019, the Company issued 30,000 shares for advisory services (Note 9(4)). The shares were valued at fair market value on the date of issuance for a total of $37,500 or $1.25 per share. On July 1, 2019, the Company issued 37,500 shares to its Chief Operating Officer (Note 6(3)). The shares were valued at fair market value on the date of issuance for a total of $49,125 or $1.31 per share. On August 8, 2019, the Company issued 50,000 shares for advisory services (Note 9(7)). The shares were valued at fair market value on the date of issuance for a total of $74,500 or $1.49 per share. On September 18, 2019, the Company issued 25,000 shares for advisory services (Note 10). The shares were valued at fair market value on the date of issuance for a total of $40,250 or $1.61 per share. There was a total of 13,079,809 and 12,872,309 shares of common stock issued and outstanding as of September 30, 2019 and December 31, 2018, respectively. Share Purchase Warrants As of September 30, 2019, and December 31, 2018, the following common stock purchase warrants were outstanding: Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised (2,000) (2) 0.40 Outstanding – December 31, 2018 52,000 0.40 Granted - - Forfeited/Canceled - - Exercised - - Outstanding – September 30, 2019 52,000 $ 0.40 (1) Each two shares of common stock purchased in a private placement offering included one warrant to purchase an additional share of common stock at an exercise price of $0.40. (2) During the year ended December 31, 2018, investors exercised warrants to purchase an aggregate of 2,000 shares of common stock and received 1,715 shares for exercises on a cashless basis. The weighted average remaining contractual term is 0.25 years. In accordance with authoritative accounting guidance, the fair value of the outstanding common stock purchase warrants was calculated using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40

Other Events

Other Events	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Other Events	Note 11 – Other Events On March 15, 2019 the Company relocated its principal executive office from Miami, Florida to 50 Battery Place, #7T, New York, New York 10280. Jonah Meer, the Company's Chief Executive Officer and a director, provides the use of this office space at no cost.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Events The Company has evaluated subsequent events from September 30, 2019 through the date these financial statements were issued and determined there are no additional events requiring disclosure. On November 4, 2019, the Company and Dartmouth entered in the First Amendment to the Sponsored Research Agreement to extend the term of the Agreement and provide for an additional year of funding through July 14, 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Financial Statement Presentation	Financial Statement Presentation: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Reclassification	Reclassification:
Fiscal year end	Fiscal year end:
Use of Estimates	Use of Estimates:
Cash Equivalents	Cash Equivalents:
Research and Development Costs	Research and Development Costs: esearch and development costs were $150,569 and $360,586 for .
Advertising and Marketing Costs	Advertising and Marketing Costs: The Company incurred $190,362 and $7,907 in advertising and marketing costs during the three months ended September 30, 2019 and 2018, respectively. The Company incurred $280,952 and $48,832 in advertising and marketing costs during the nine months ended September 30, 2019 and 2018, respectively.
Related parties	Related parties:
Stock-Based Compensation and Other Share-Based Payments	Stock-Based Compensation and Other Share-Based Payments: The Company accounts for stock compensation arrangements with non-employees in accordance with ASU 2018-07 which requires that such equity instruments are recorded at the value on the grant date. For stock options granted to employees, directors, and non-employees, the fair value of the stock options is estimated using a Black-Scholes valuation model.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 820, "Fair Value Measurements and Disclosures", defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company's derivative liabilities as of September 30, 2019 and December 31, 2018: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2019: Liabilities Derivative liabilities $ - $ - $ 44,456 As of December 31, 2018: Liabilities Derivative liabilities $ - $ - $ 36,827
Warrants	Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity"
Income taxes	Income taxes:
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the periods ended September 30, 2019 and December 31, 2018 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: September 30, 2019 December 31, 2018 Stock purchase warrants 52,000 52,000 Research Warrants at 3% of issued and outstanding shares 392,394 386,170 Convertible Notes 37,690 27,864 Series A Preferred shares 700 700 Stock options vested 1,553,336 1,486,670 Stock options not yet vested 161,664 128,330 Total 2,197,784 2,081,734
New Accounting Pronouncements	New Accounting Pronouncements: In June 2018, an accounting update was issued by FASB to simplify the accounting for nonemployee share-based payment transactions resulting from expanding the scope of ASC Topic 718, "Compensation-Stock Compensation ASC Topic 718 ASC Topic 718 ASC Topic 718 ASC Topic 606, Revenue from Contracts with Customers

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of the fair value of derivative liabilities	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2019: Liabilities Derivative liabilities $ - $ - $ 44,456 As of December 31, 2018: Liabilities Derivative liabilities $ - $ - $ 36,827
Schedule of potentially dilutive securities	September 30, 2019 December 31, 2018 Stock purchase warrants 52,000 52,000 Research Warrants at 3% of issued and outstanding shares 392,394 386,170 Convertible Notes 37,690 27,864 Series A Preferred shares 700 700 Stock options vested 1,553,336 1,486,670 Stock options not yet vested 161,664 128,330 Total 2,197,784 2,081,734

Convertible Note - Related Pa_2

Convertible Note - Related Party and Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Schedule of convertible notes	September 30, 2019 December 31, 2018 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - - Carrying value $ 25,000 $ 25,000
Schedule of fair value of conversion feature	Balance at December 31, 2017 $ 31,090 Derivative addition associated with convertible notes - Change in fair value 5,737 Balance at December 31, 2018 36,827 Change in fair value 7,629 Balance at September 30, 2019 $ 44,456
Schedule of fair value at commitment and re-measurement dates derivative liabilities	Commitment Date September 30, 2019 December 31, 2018 Expected dividends 0 0 0 Expected volatility 101% ~103% 206.53% ~ 214.23% 64% ~ 65% Expected term 0.92 ~ 1 year 0.92 ~ 0.99 year 0.67 ~ 0.74 year Risk free interest rate 1.33% 1.75% 2.60%

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Schedule of fees incurred as general and administrative expenses relative contract	Stock option $ 53,307 Stock award 49,125 Services fees 36,000 $ 138,432

Stock Plan (Tables)

Stock Plan (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of stock award	September 30, September 30, 2019 2018 Number of shares vested in period 92,500 10,000 Weighted average fair market value per share $ 1.37 $ 2.8 Stock based compensation recognized $ 126,875 $ 28,000
Stock option compensation allocated as research and development expenses	Three Months ended Nine Months ended September 30, September 30, 2019 2018 2019 2018 Research and development expenses $ 38,753 $ 48,078 $ 126,686 $ 122,816 Three Months ended Nine Months ended September 30, September 30, 2019 2018 2019 2018 General and administrative expenses $ 53,307 $ 353,430 $ 53,307 $ 1,060,290
Schedule of fair value options assumptions	Measurement date Dividend yield 0% Expected volatility 114.69 ~ 129.08% Risk-free interest rate 1.79% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 1.31 ~ 2.80 Exercise Price $ 0.40 ~ 2.00
Schedule of stock options	September 30, 2019 December 31, 2018 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 1,615,000 $ 1.97 670,000 $ 1.93 Granted 100,000 $ 2 945,000 $ 2.00 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 1,715,000 $ 1.97 1,615,000 $ 1.97 Options exercisable, end of period 1,553,336 $ 1.98 1,486,670 $ 1.98 Options expected to vest, end of period 161,664 $ 1.85 128,330 $ 1.81 Weighted average fair value of options granted $ 2.12 $ 2.19

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of common stock purchase warrants were outstanding	Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised (2,000) (2) 0.40 Outstanding – December 31, 2018 52,000 0.40 Granted - - Forfeited/Canceled - - Exercised - - Outstanding – September 30, 2019 52,000 $ 0.40 (1) Each two shares of common stock purchased in a private placement offering included one warrant to purchase an additional share of common stock at an exercise price of $0.40. (2) During the year ended December 31, 2018, investors exercised warrants to purchase an aggregate of 2,000 shares of common stock and received 1,715 shares for exercises on a cashless basis.
Schedule of fair value warrants assumptions	Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Level 2 [Member]
Liabilities
Derivative liabilities
Level 3 [Member]
Liabilities
Derivative liabilities	44,456	36,827
Level 1 [Member]
Liabilities
Derivative liabilities

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Potentially dilutive securities net loss per share	2,197,784	2,081,734
Stock options not yet vested [Member]
Potentially dilutive securities net loss per share	161,664	128,330
Stock purchase warrants [Member]
Potentially dilutive securities net loss per share	52,000	52,000
Series A Preferred shares [Member]
Potentially dilutive securities net loss per share	700	700
Research Warrants at 3% of issued and outstanding shares [Member]
Potentially dilutive securities net loss per share	392,394	386,170
Convertible Notes [Member]
Potentially dilutive securities net loss per share	37,690	27,864
Stock options vested [Member]
Potentially dilutive securities net loss per share	1,553,336	1,486,670

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Summary of Significant Accounting Policies (Textual)
Reclassified research and development expense		$ 45,691		$ 122,816
Research and development costs	$ 136,080	150,469	$ 439,608	360,586
Advertising or marketing costs	$ 190,362	$ 7,907	$ 280,952	$ 48,832
Research warrants issued and outstanding, percentage			3.00%

Convertible Note - Related Pa_3

Convertible Note - Related Party and Derivative Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Face value of certain convertible notes	$ 25,000	$ 25,000
Less: unamortized discount
Carrying value	$ 25,000	$ 25,000

Convertible Note - Related Pa_4

Convertible Note - Related Party and Derivative Liabilities (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Balance	$ 36,827
Derivative addition associated with convertible notes
Change in fair value	7,629	5,737
Balance	$ 44,456	$ 36,827

Convertible Note - Related Pa_5

Convertible Note - Related Party and Derivative Liabilities (Details 2)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Expected dividends	0.00%	0.00%
Risk free interest rate	1.75%	2.60%
Commitment Date [Member]
Expected dividends	0.00%
Risk free interest rate	1.33%
Maximum [Member]
Expected volatility	214.23%	65.00%
Expected term	11 months 26 days	8 months 26 days
Maximum [Member] | Commitment Date [Member]
Expected volatility	103.00%
Expected term	1 year
Minimum [Member]
Expected volatility	206.53%	64.00%
Expected term	11 months 1 day	8 months 1 day
Minimum [Member] | Commitment Date [Member]
Expected volatility	101.00%
Expected term	11 months 1 day

Convertible Note - Related Pa_6

Convertible Note - Related Party and Derivative Liabilities (Details Textual) - Cubesquare Llc [Member] - USD ($)	Sep. 09, 2018	Sep. 28, 2017	Sep. 27, 2017	Sep. 01, 2016
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling			$ 15,000	$ 10,000
Interest rate per annum			8.00%	8.00%
Conversion, description			Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion.	(i) the greater of a discountof 75% to $0.25 per share or $0.0625 per share if the Company's shares are not trading on a public market; and (ii) if the shares are listed for trading on a public market a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion.
Maturity date				Sep. 1, 2017
Maturity date, description	Note 2 was amended to extend the maturity date until September 27, 2019. On September 27, 2019, Note 2 was amended to extend the maturity date until September 27, 2020.	Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; and on September 1, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020, under the same terms and conditions.
Debt instument due date			Sep. 27, 2018
President [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Ownership percentage				25.00%

Unsecured Short-Term Advance _2

Unsecured Short-Term Advance from Third Party (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Unsecured Short-Term Advance from Third Party (Textual)
Unsecured short-term advances	$ 100,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Related Party Transactions [Abstract]
Stock option	$ 53,307	$ 1,060,290
Stock award	49,125
Services fees	36,000
Total	$ 138,432

Related Party Transactions (D_2

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended
	Jun. 25, 2019	Mar. 01, 2019	Sep. 30, 2019	Aug. 20, 2019	Aug. 01, 2019	Dec. 31, 2018
Related Party Transactions (Textual)
Advances from related parties			$ 50,000
Payments to various vendors in accumulated amount			(6,456,910)			$ (5,523,708)
Cubesquare Llc [Member]
Related Party Transactions (Textual)
Promissory note principal amount		$ 50,000
Interest rate per annum		8.00%
Jonah Meer [Member]
Related Party Transactions (Textual)
Advances from related parties					$ 50,000
Payments to various vendors in accumulated amount			14,155
Accounts payable, related party			$ 14,155
Ido Merfeld [Member]
Related Party Transactions (Textual)
Advances from related parties				$ 50,000
Dr. Bonfiglio [Member]
Related Party Transactions (Textual)
Commitment, description	(i) 50,000 shares of common stock of the Company, 37,500 of which shares vested upon issuance on July 1, 2019 and 12,500 of which shares will vest on the earlier of (i) January 1, 2020 and (ii) the date the Company raises equity capital of $500,000 as described in the Term Sheet, provided Dr. Bonfiglio is in the employ of the Company on such date. The Term Sheet also provides for the grant of a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares will vest upon grant and 25,000 shares will vest on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio is in the employ of the Company on such dates and further provided that if the Company raises equity capital of $1.5 million before December 31, 2019, unvested shares subject to the option will immediately vest and become exercisable, so long as Dr. Bonfiglio is in the Company's employ on such date.
Equity capital, description	The Company raises equity capital of $1.5 million by April 1, 2020, Dr. Bonfiglio will be appointed to the Company's board of directors. In addition, Dr. Bonfiglio will be entitled to a salary of $12,000 per month which will be deferred and payable at the rate of 5% of equity capital raised by the Company up to $12,000 per month.

License and Research Funding _2

License and Research Funding Agreements (Details) - USD ($)

Mar. 06, 2018

Dec. 13, 2017

Dec. 14, 2016

Dec. 12, 2016

Apr. 23, 2018

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Sep. 30, 2018

Mar. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

License and Research Funding Agreements (Textual)

Research and development costs

$ 136,080

$ 150,469

$ 439,608

$ 360,586

Shares issued for advisory services, value

75,000

Shares issued, value

$ 25,000

$ 40,000

$ 25,000

$ 500,000

License and research funding agreement compensation paid, description

The Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.

The Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.

Ariel University [Member]

License and Research Funding Agreements (Textual)

Shares issued for advisory services, value

119,950

Shares issued, value

$ 335,860

Shares issued, percentage

1.00%

Licensing Agreements [Member]

License and Research Funding Agreements (Textual)

Total amount of fund for research during research period

$ 100,000

Warrant exercisable percentage

4.00%

Payments of completion of milestone events, description

Upon successful clinical FDA Phase II completion - $130,000; and Upon successful clinical FDA Phase III completion - $390,000

Payments of completion of milestone events due

6 months

Services Agreement [Member]

License and Research Funding Agreements (Textual)

License and research funding agreement compensation paid, description

The Second Amendment also provides that the Company pay Ariel $17,250 within 30 days of the date of the Amendment and an additional $17,250 on or before May 1, 2019. All other terms and conditions of the Services Agreement not amended remain in effect.

Intellectual Property License_2

Intellectual Property License Agreement (Details) - USD ($)	Oct. 02, 2019	Sep. 30, 2019
Intellectual Property License Agreement (Textual)
Intellectual property license agreement		Under the Agreement, the Company must diligently proceed with the development, manufacture and sale of licensed products and licensed services, including funding at least $1,000,000 of research in each calendar year beginning in 2019 and ending with the first commercial sale of a licensed product; filing an IND/BLA (or equivalent) with the FDA or a comparable European regulatory agency before the four-year anniversary of the Effective Date, make the first commercial sale of a licensed product.
Subsequent Event [Member]
Intellectual Property License Agreement (Textual)
Intellectual property license agreement	As consideration for the license grant, the Company will pay Dartmouth: (i) a license issue fee of $25,000; (ii) an annual license maintenance fee of $25,000, commencing on the first anniversary of the Effective Date until the date of the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales (as defined in the Agreement) of licensed products and services by the Company or a sublicensee; (v)15% of all consideration received by the Company under a sublicense; and (vi) beginning as of the date of the first commercial sale, an annual minimum royalty payment of $500,000 in the first calendar year after the first commercial sale, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter.
Prepaid license fee	$ 25,000

Commitments (Details)

Commitments (Details) - USD ($)

Nov. 04, 2019

Sep. 18, 2019

Aug. 08, 2019

Dec. 12, 2018

Jul. 12, 2018

Jun. 23, 2018

Apr. 12, 2018

Jan. 28, 2019

Apr. 23, 2018

Jan. 23, 2018

Nov. 15, 2017

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Oct. 02, 2019

Aug. 22, 2018

Aug. 15, 2018

May 01, 2018

Apr. 26, 2018

Apr. 16, 2018

Mar. 19, 2018

Dec. 14, 2017

Commitments (Textual)

Compensation for the services provided

$ 17,250

$ 17,250

Compensation cost

$ 26,594

$ 49,885

Option granted, advisors

[1]

Service agreement payment, description

The Company of an additional monthly fee, commencing March 2018, of up to $2,200 (8,000 Israeli shekels) as compensation for additional costs which the Company may request.

Prepaid expenses

$ 7,187

$ 16,531

Consulting fee

$ 5,000

Investor relations agreement, description

The Company entered into a six-month services agreement with PCG Advisory, Inc. ("PCG") under which agreement PCG will provide investor relations and capital market advisory services to the Company. In consideration therefor, the Company will pay PCG a monthly cash fee of $5,000 ($2,500 of which will be deferred until the Company raises at least $300,000 in a financing) and issued 50,000 shares of its common stock on August 8, 2019.After the initial six-month term, the agreement will automatically renew on a month-to-month basis unless either party notifies the other of its desire to terminate the agreement or by the Company if PCG fails to comply with securities laws, makes an untrue statement of material facts or omits to state any material fact in connection with an investment in the Company or breaches a representation, warranty or covenant in the agreement.

The Company gave notice of rescission of the agreement to such firm. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.

The Company entered into a six-month investor relations agreement with an investor relations firm for a monthly consulting fee of $5,000 and the issuance of 75,000 shares of common stock payable on signing the agreement.

Paid for additional fees

16,935

Issuance of common stock payable

75,000

Subsequent Event [Member]

Commitments (Textual)

Outstanding expenses

$ 25,000

Advisory Board Business Advisor [Member]

Commitments (Textual)

Advisory board member consulting agreement description

The Company entered into a one-year advisory board member consulting agreement with Derrick Chambers under which Mr. Chambers will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 25,000 shares of its common stock to Mr. Chambers under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance.

Equity Option [Member]

Commitments (Textual)

Option granted, advisors

10,000

20,000

Stock option and advisor granted

30,000

20,000

30,000

Issuance of common stock payable

30,000

Sponsored Research Agreement [Member]

Commitments (Textual)

Prepaid expenses

45,366

9,073

Prepaid expensed during period

0

27,220

Sponsored research agreement, description

The Company entered into a one-year Sponsored Research Agreement with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and funded an additional $18,147 on December 17, 2018 and funded an additional $18,146 on June 20, 2019.

Sponsored Research Agreement [Member] | Subsequent Event [Member]

Commitments (Textual)

Sponsored research agreement extended term

Jul. 14, 2020

Service Agreement With Ariel [Member]

Commitments (Textual)

Compensation for the services provided

41,160

$ 20,580

$ 20,580

$ 17,250

Compensation cost

10,290

Service agreement payment, description

The Company further amended the Services Agreement with Ariel (the "Second Amendment") to extend the term thereof for an additional twelve-month period until December 14, 2019. The Second Amendment also provides that the Company pay Ariel $17,250 within 30 days of the date of the Amendment and an additional $17,250 on or before May 1, 2019.

Prepaid expenses

27,440

$ 24,010

Prepaid expensed during period

$ 0

$ 6,860

[1]

Each two shares of common stock purchased in a private placement offering included one warrant to purchase an additional share of common stock at an exercise price of $0.40.

Stock Plan (Details)

Stock Plan (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement [Abstract]
Number of shares vested in period	92,500	10,000
Weighted average fair market value per share	$ 1.37	$ 2.8
Stock based compensation recognized	$ 126,875	$ 28,000

Stock Plan (Details 1)

Stock Plan (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and Development Expense [Member]
Stock option compensation allocated expenses	$ 38,753	$ 48,078	$ 126,686	$ 122,816
General and Administrative Expense [Member]
Stock option compensation allocated expenses	$ 53,307	$ 353,430	$ 53,307	$ 1,060,290

Stock Plan (Details 2)

Stock Plan (Details 2) - Measurement Date [Member] - Equity Option [Member]	9 Months Ended
	Sep. 30, 2019$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Exercise Price, Minimum	$ 0.40
Exercise Price, Maximum	$ 2
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	114.69%
Risk-free interest rate	1.79%
Expected life (years)	3 years
Stock Price	$ 1.31
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	129.08%
Risk-free interest rate	2.68%
Expected life (years)	5 years
Stock Price	$ 2.80

Stock Plan (Details 3)

Stock Plan (Details 3) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Shares Outstanding, beginning of period	1,615,000	670,000
Shares, Granted	100,000	945,000
Shares, Exercised
Shares, Canceled
Shares Outstanding, end of period	1,715,000	1,615,000
Shares Options exercisable, end of period	1,553,336	1,486,670
Shares, Options expected to vest, end of period	161,664	128,330
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 1.97	$ 1.93
Weighted Average Shares Exercise Price, Granted	2	2
Weighted Average Shares Exercise Price, Exercised
Weighted Average Shares Exercise Price, Canceled
Weighted Average Shares Exercise Price, Outstanding, end of period	1.97	1.97
Weighted Average Exercise Price, Options exercisable, end of period	1.98	1.98
Weighted Average Exercise Price, Options expected to vest, end of period	1.85	1.81
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 2.12	$ 2.19

Stock Plan (Details Textual)

Stock Plan (Details Textual) - USD ($)

Sep. 18, 2019

Jul. 02, 2019

Jun. 25, 2019

Dec. 10, 2018

Aug. 15, 2018

Dec. 14, 2017

Dec. 04, 2017

Dec. 14, 2016

Apr. 16, 2018

Nov. 15, 2017

Sep. 30, 2019

Jan. 28, 2019

Jan. 23, 2018

Stock Plan (Textual)

Total unrecognized compensation remaining to be recognized in future periods

$ 71,402

Dr. Bonfiglio [Member]

Stock Plan (Textual)

Share based payment award terms of award

In connection with the Term Sheet, on July 1, 2019, Dr. Bonfiglio was granted (i) 50,000 shares of common stock of the Company, 37,500 of which shares vested upon issuance on July 1, 2019 and 12,500 of which shares will vest on the earlier of (i) January 1, 2020 and (ii) the date the Company raises equity capital of $500,000, provided Dr. Bonfiglio is in the employ of the Company on such date.

Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares will vest upon grant and 25,000 shares will vest on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio is in the employ of the Company on such dates and further provided that if the Company raises equity capital of $1.5 million before December 31, 2019, unvested shares subject to the option will immediately vest and become exercisable, so long as Dr. Bonfiglio is in the Company's employ on such date.

Board of Directors Chairman [Member]

Stock Plan (Textual)

Stock award

440,000

Receive common stock vest upon grant date

150,000

Vested shares

145,000

145,000

Equity Option [Member]

Stock Plan (Textual)

Reserved shares for issuance

10,000,000

Stock award

10,000

Description of services agreement

Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 6,667 shares of common stock, exercisable on August 15, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 6,667 shares of common stock exercisable on August 15, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 6,666 shares of common stock exercisable on August 15, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company.

Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company.

Under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.

Stock Option One [Member]

Stock Plan (Textual)

Stock award

30,000

Description of services agreement

Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.

2016 Stock Option and Stock Award Plan [Member]

Stock Plan (Textual)

Vested shares

25,000

Stock Options Granted To Officers [Member]

Stock Plan (Textual)

Total unrecognized compensation remaining to be recognized in future periods

$ 36,473

Weighted average exercise price

$ 2

$ 2

Shares of common stock under certain vesting terms

5 years

5 years

Vest and exercisable date

Dec. 4, 2018

Granted an option to purchase shares of common stock

325,000

300,000

Stock Options Granted Employees [Member]

Stock Plan (Textual)

Description of services agreement

(i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company.

Weighted average exercise price

$ 2

Shares of common stock under certain vesting terms

5 years

Granted an option to purchase shares of common stock

145,000

Stock-based compensation

$ 54,840

December Fourteen Two Zero One Eight [Member] | Board of Directors Chairman [Member]

Stock Plan (Textual)

Vested shares

145,000

Fourth Quarter [Member] | Stock Awards Not Yet Vested [Member]

Stock Plan (Textual)

Vested shares

290,000

Capital Stock (Details)

Capital Stock (Details) - $ / shares		9 Months Ended	12 Months Ended
		Sep. 30, 2019	Dec. 31, 2018
Equity [Abstract]
Warrants Outstanding Beginning	[1]	52,000	54,000
Warrants Granted	[1]
Warrants Forfeited/Canceled	[1]
Warrants Exercised	[1]		(2,000)	[2]
Warrants Outstanding Ending	[1]	52,000	52,000
Weighted Average Exercise Price Outstanding Beginning		$ 0.40	$ 0.40
Weighted Average Exercise Price Granted
Weighted Average Exercise Price Forfeited/Canceled
Weighted Average Exercise Price Exercised			0.40	[2]
Weighted Average Exercise Price Outstanding Ending		$ 0.40	$ 0.40
[1]	Each two shares of common stock purchased in a private placement offering included one warrant to purchase an additional share of common stock at an exercise price of $0.40.
[2]	During the year ended December 31, 2018, investors exercised warrants to purchase an aggregate of 2,000 shares of common stock and received 1,715 shares for exercises on a cashless basis.

Capital Stock (Details 1)

Capital Stock (Details 1) - Measurement Date [Member] - Warrant [Member]	9 Months Ended
	Sep. 30, 2019$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Stock Price	$ 0.25
Exercise Price	$ 0.40
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.90%
Risk-free interest rate	1.47%
Expected life (years)	2 years 8 months 16 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	119.33%
Risk-free interest rate	1.60%
Expected life (years)	2 years 11 months 1 day

Capital Stock (Details Textual)

Capital Stock (Details Textual) - USD ($)	Aug. 08, 2019	Jul. 02, 2019	Sep. 18, 2019	Jan. 28, 2019	Sep. 30, 2019	Jun. 30, 2018	Sep. 30, 2019	Dec. 31, 2018
Series A Preferred Shares, par value					$ 0.001		$ 0.001	$ 0.001
Series A Preferred Shares, authorized					10,000		10,000	10,000
Series A Preferred Shares, shares issued					2,000		2,000	2,000
Series A Preferred Shares, shares outstanding					2,000		2,000	2,000
Common stock, par value					$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares authorized					100,000,000		100,000,000	100,000,000
Common stock, shares issued					13,079,809		13,079,809	12,872,309
Common stock, shares outstanding					13,079,809		13,079,809	12,872,309
Shares issued for stock awards for business advisory services					$ 74,500	$ 150,000
Warrants received underlying shares for exercise on a cashless basis								1,715
Weighted average remaining contractual term							2 months 30 days
Sale of stock description of transaction							Each two shares of common stock purchased in a private placement offering included one warrant to purchase an additional share of common stock at an exercise price of $0.40.
Number of securities called by warrants or rights								2,000
Preferred stock voting rights							The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding.
Preferred stock redeemable description							The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value").
Chief Operating Officer [Member]
Shares issued for stock awards for business advisory services, shares		37,500
Shares issued for stock awards for business advisory services		$ 49,125
Share price per share		$ 1.31
Subscription Agreement [Member]
Shares issued for stock awards for business advisory services, shares							65,000
Shares issued for stock awards for business advisory services							$ 65,000
Advisory Services
Shares issued for stock awards for business advisory services, shares	50,000		25,000	30,000
Shares issued for stock awards for business advisory services	$ 74,500		$ 40,250	$ 37,500
Share price per share	$ 1.49		$ 1.61	$ 1.25